Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bandwidth Inc (BAND) vs Mesoblast Limited (MESO) Price & Performance

Bandwidth IncTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Bandwidth Inc vs Mesoblast Limited — how do they compare? Bandwidth Inc trades at $53.96 (market cap $1.67B), while Mesoblast Limited trades at $15.7 (market cap $2.20B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Bandwidth Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

BANDMESO
Market Cap
$1.67B$2.20B
Sector
TechnologyTechnology
52-Week High
$78.44$20.96
52-Week Low
$12.82$12.88
Enterprise Value
$2.05B$2.20B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bandwidth Inc

Bandwidth (BAND) trades at $51.97, up 0.68% with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results with 22% revenue growth and raised full-year guidance, though profitability remains thin with a 0.27% net margin. Analyst sentiment is overwhelmingly positive with a $80.33 consensus price target representing 55% upside potential.

The outlook is promising given accelerating AI-driven communications demand and enterprise wins, but investors face valuation concerns with elevated EV/EBITDA of 34.27. Key risks include execution on growth targets and competitive pressures in the cloud communications space. The stock's recent 21.7% weekly gain suggests momentum but warrants caution near technical resistance.

Mesoblast Limited

MESO trades at $16.78, down 0.83% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company shows strong revenue growth with Ryoncil generating $115 million in its first full year, though it remains unprofitable with a -144.33% net income margin. Recent developments include achieving Phase 3 trial targets for chronic back pain and securing a $50 million non-dilutive facility.

MESO presents a high-risk, high-reward opportunity with significant commercial traction but persistent losses. The bullish analyst consensus and recent regulatory progress support upside potential, though profitability concerns and high P/S ratio of 30.52 warrant caution for risk-averse investors.

Returns comparison

Trailing returns across standard periods

About Bandwidth Inc

Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.

Read more on BAND

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO